Literature DB >> 30737830

Skin nerve pathology: Biomarkers of premanifest and manifest amyloid neuropathy.

Chi-Chao Chao1, Hsueh-Wen Hsueh1, Hung-Wei Kan2, Chun-Hua Liao2, Hao-Hua Jiang2, Hao Chiang2, Whei-Min Lin2, Ti-Yen Yeh2, Yea-Huey Lin1, Ya-Yin Cheng2, Sung-Tsang Hsieh1,2,3,4,5.   

Abstract

OBJECTIVE: Small-fiber sensory and autonomic symptoms are early presentations of familial amyloid polyneuropathy (FAP) with transthyretin (TTR) mutations. This study aimed to explore the potential of skin nerve pathologies as early and disease-progression biomarkers and their relationship with skin amyloid deposits.
METHODS: Skin biopsies were performed in patients and carriers to measure intraepidermal nerve fiber (IENF) density, sweat gland innervation index of structural protein gene product 9.5 (SGII[PGP9.5]) and peptidergic vasoactive intestinal peptide (SGII[VIP]), and cutaneous amyloid index. These skin pathologies were analyzed with clinical disability assessed by FAP stage score (stage 0-4) and compared to neurophysiological and psychophysical tests.
RESULTS: There were 70 TTR-mutant subjects (22 carriers and 48 patients), and 66 cases were TTR-A97S. Skin nerve pathologies were distinct according to stage. In carriers, both skin denervation and peptidergic sudomotor denervation were evident: (1) IENF density was gradually reduced from stage 0 through 4, and (2) SGII(VIP) was markedly reduced from stage 1 to 2. In contrast, SGII(PGP9.5) was similar between carriers and controls, but it declined in patients from stage 2. Skin amyloids were absent in carriers and became detectable from stage 1. Cutaneous amyloid index was correlated with SGII(PGP9.5) and stage in a multivariate mixed-effect model. When all tests were compared, only IENF density, SGII(PGP9.5), and cutaneous amyloid index were correlated with stage, and IENF density had the highest abnormal rate in carriers.
INTERPRETATION: Biomarkers of sensory and sudomotor innervation exhibited a stage-dependent progression pattern, with sensory nerve degeneration as the early skin nerve pathology. Ann Neurol 2019;85:560-573.
© 2019 American Neurological Association.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30737830     DOI: 10.1002/ana.25433

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  7 in total

Review 1.  Multidisciplinary Approaches for Transthyretin Amyloidosis.

Authors:  Haruki Koike; Takahiro Okumura; Toyoaki Murohara; Masahisa Katsuno
Journal:  Cardiol Ther       Date:  2021-06-04

2.  Vagus nerve ultrasound in transthyretin familial amyloid polyneuropathy: A pilot study.

Authors:  Kang Du; Ke Xu; Xujun Chu; Yuwei Tang; He Lv; Wei Zhang; Zhaoxia Wang; Yun Yuan; Lingchao Meng
Journal:  J Neuroimaging       Date:  2021-12-29       Impact factor: 2.324

3.  Cardiomyopathy correlates to nerve damage in p.A117S late-onset transthyretin amyloid polyneuropathy.

Authors:  Yen-Hung Lin; Hsueh-Wen Hsueh; Mao-Yuan Su; Mei-Fang Cheng; Ming-Chang Chiang; Jyh-Ming Jimmy Juang; Yi-Hui Kao; Kai-Chieh Chang; Fang-Ping Feng; Sung-Tsang Hsieh; Chi-Chao Chao
Journal:  Ann Clin Transl Neurol       Date:  2022-08-09       Impact factor: 5.430

4.  Cutaneous amyloid is a biomarker in early ATTRv neuropathy and progresses across disease stages.

Authors:  Roy Freeman; Alejandra Gonzalez-Duarte; Fabio Barroso; Marta Campagnolo; Sharika Rajan; Jennifer Garcia; Jee Young Kim; Ningshan Wang; Lucas Orellana; Christopher Gibbons
Journal:  Ann Clin Transl Neurol       Date:  2022-08-09       Impact factor: 5.430

Review 5.  Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy.

Authors:  David Adams; Yukio Ando; João Melo Beirão; Teresa Coelho; Morie A Gertz; Julian D Gillmore; Philip N Hawkins; Isabelle Lousada; Ole B Suhr; Giampaolo Merlini
Journal:  J Neurol       Date:  2020-01-06       Impact factor: 4.849

Review 6.  C-Fiber Assays in the Cornea vs. Skin.

Authors:  Eric A Moulton; David Borsook
Journal:  Brain Sci       Date:  2019-11-12

7.  Diagnostic criteria for small fibre neuropathy in clinical practice and research.

Authors:  Grazia Devigili; Sara Rinaldo; Raffaella Lombardi; Daniele Cazzato; Margherita Marchi; Erika Salvi; Roberto Eleopra; Giuseppe Lauria
Journal:  Brain       Date:  2019-12-01       Impact factor: 13.501

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.